Sanofi and Lexicon Pharmaceuticals Enter Collaboration on Diabetes Therapy Sotagliflozin
News
Sanofi and Lexicon Pharmaceuticals, Inc., recently announced the start of a new partnership and license agreement for the development and commercialization of sotagliflozin, a novel orally-delivered investigational dual inhibitor of sodium-glucose cotransporters ... Read more